EXEL at a glance
Exelixis Inc (EXEL, SEC CIK 939767) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as August 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended January 2, 2026 (FY2025), Exelixis Inc (EXEL) reported revenue of $2.3 billion (up 7.0% from FY2024) and net income of $782.6 million. Diluted EPS was $2.78.
- As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Exelixis Inc (EXEL) shares worth $7.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Beckerle Mary C on August 10, 2026 of 9,812 shares at $53.66 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.3B
- +7.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 38 funds
- $7.3B · −1 vs prior quarter
- Latest 8-K
- Oct 29, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Oct 2, 2026
Risk Factors
- No material changes to risk factors disclosed in Fiscal 2025 Form 10-K
- Carried-forward business risk: unidentified or currently immaterial risks may impair operations
- Carried-forward financial risk: existing risks could materially adversely affect financial condition and results of operations
Management Discussion & Analysis
- Total revenue $658.7M vs $597.8M YoY, up $60.9M
- Net income $218.1M vs $193.6M YoY, with effective tax rate 22.9% vs 23.3%
- Best product CABOMETYX revenue $603.2M vs $539.9M, up $63.3M
- Cash, equivalents and securities $1.4B vs $1.7B at December 31, 2025
- Operating cash flow $839.5M, stock repurchases $402.1M through September 30, 2026
- Outlook: revenue may increase, while reimbursement pressure, tariffs and generic competition remain headwinds
AI summary of the EXEL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Exelixis reported financial results for the quarter ended October 2, 2026
- Corporate update included in Exhibit 99.1, the key source for detailed results and guidance
Item EX-99.1: Item EX-99.1
- Q3 revenue $658.7M vs $597.8M, driven by cabozantinib product revenue of $604.9M
- GAAP diluted EPS $0.85 vs $0.69, supported by 8.2% lower diluted shares from repurchases
Item 8.01: Other Events
- FDA review of zanzalintinib plus atezolizumab for metastatic colorectal cancer extended three months
- Updated PDUFA action date: March 3, 2027
Item 8.01: Other Events
- Federal Circuit affirmed validity of three patents protecting Exelixis’ product
- MSN generic launch blocked until January 15, 2030, subject to appeals and regulatory exclusivity
AI summaries of EXEL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for EXEL
Don't miss the next EXEL filing
- Alerts as it files. A push when EXEL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut EXEL, by share count.
- Ask anything. An AI agent that reads every EXEL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Beckerle Mary C | Sell | Aug 10, 2026 | 9,812 | $53.66 |
| Beckerle Mary C | A | May 27, 2026 | 8,367 | - |
| PAPADOPOULOS STELIOS | A | May 27, 2026 | 8,367 | - |
| JOHNSON DAVID EDWARD | A | May 27, 2026 | 19,133 | - |
| Freire Maria C | A | May 27, 2026 | 8,367 | - |
| Oliver Bob | A | May 27, 2026 | 8,367 | - |
| POSTE GEORGE | A | May 27, 2026 | 8,367 | - |
| WYSZOMIERSKI JACK L | A | May 27, 2026 | 8,367 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.2B | $2.3B |
| Operating Income | - | $604.6M | $872.2M |
| Net Income | $207.8M | $521.3M | $782.6M |
| Op. Margin | - | 27.9% | 37.6% |
| Net Margin | - | 24.0% | 33.7% |
| Balance Sheet | |||
| Total Assets | $2.9B | $2.9B | $2.8B |
| Equity | - | $2.2B | $2.2B |
| ROE | - | 23.2% | 36.2% |
| Per Share | |||
| EPS | $0.65 | $1.76 | $2.78 |
| Cash Flow | |||
| Operating CF | - | $700.0M | $884.3M |
| CapEx | $40.5M | $28.4M | $8.4M |
Source: XBRL data in Exelixis Inc (EXEL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate EXEL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 38 | $7.28B |
| Q2 2026 | 39 | $6.99B |
| Q1 2026 | 38 | $5.56B |
| Q4 2025 | 33 | $5.62B |
| Q3 2025 | 36 | $5.19B |
| Q2 2025 | 33 | $5.70B |
| Q1 2025 | 32 | $3.45B |
| Q4 2024 | 27 | $2.87B |
- Morgan Stanley+1.79M (+40%)
- BlackRock+668.1K (+2%)
- State Street Corp+551.4K (+6%)
- Invesco Ltd+370.3K (+8%)
- Raymond James Financial+231.2K (+25%)
- AQR Capital Management−1.42M (-13%)
- Goldman Sachs Group−978.2K (-36%)
- Two Sigma Investments−957.0K (-23%)
- Millennium Management−863.8K (-71%)
- Renaissance Technologies LLC−635.3K (-5%)
- FMR LLC (Fidelity)−1.15M
- Blackstone Group−12.7K
- Equitable Holdings Inc−7.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 276 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
EXEL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Oct 29, 2026 | Oct 2, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 8-K | Sep 11, 2026 | - | Analysis | - |
| 8-K | Aug 31, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jul 3, 2026 | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 8-K | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 8-K | May 5, 2026 | - | - | - |
| 10-Q | May 5, 2026 | Apr 3, 2026 | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
EXEL SEC filings: frequently asked questions
Which institutions hold EXEL stock?
As of September 30, 2026, the largest Exelixis Inc (EXEL) holders among the 13F filers tracked by SignalX were BlackRock ($1.7 billion), Renaissance Technologies LLC ($747.2 million), Vanguard Portfolio Management LLC ($698.3 million), Vanguard Capital Management LLC ($628.4 million), State Street Corp ($614.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was EXEL's revenue in fiscal year 2025?
For the fiscal year ended January 2, 2026 (FY2025), Exelixis Inc (EXEL) reported revenue of $2.3 billion (up 7.0% from FY2024) and net income of $782.6 million. Diluted EPS was $2.78. The figures come from the XBRL data in the 10-K.
What did EXEL report in its latest 8-K?
Exelixis Inc (EXEL) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Exelixis reported financial results for the quarter ended October 2, 2026.
What are the latest EXEL SEC filings?
Exelixis Inc (EXEL) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on August 12, 2026.
What is EXEL's SEC CIK number?
Exelixis Inc (EXEL)'s SEC Central Index Key (CIK) is 939767. EDGAR lists every EXEL filing under that number.
Ask anything about EXEL
The research agent reads EXEL's filings, financials, insider trades and 13F holders, then answers with sources.